{"entities":{"Q9894":{"pageid":14055,"ns":120,"title":"Item:Q9894","lastrevid":205047,"modified":"2020-05-20T22:05:49Z","type":"item","id":"Q9894","labels":{"en":{"language":"en","value":"Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5"}},"descriptions":{"en":{"language":"en","value":"Cited in: \"Targeting cancer stem cell pathways for cancer therapy\" in Signal Transduct Target Ther; 2020 ; 5 8"}},"aliases":[],"claims":{"P17":[{"mainsnak":{"snaktype":"value","property":"P17","datavalue":{"value":{"entity-type":"item","numeric-id":7916,"id":"Q7916"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q9894$12AC5ECC-F04B-4433-A0AC-5673F231BF14","rank":"normal"}],"P94":[{"mainsnak":{"snaktype":"value","property":"P94","datavalue":{"value":{"entity-type":"item","numeric-id":8449,"id":"Q8449"},"type":"wikibase-entityid"},"datatype":"wikibase-item"},"type":"statement","id":"Q9894$B5153941-C455-44D0-B2E0-2895090BDE28","rank":"normal"}],"P149":[{"mainsnak":{"snaktype":"value","property":"P149","datavalue":{"value":"Cooper TM","type":"string"},"datatype":"string"},"type":"statement","id":"Q9894$FF940F50-B46B-4210-BD79-143A17295F66","rank":"normal"}],"P100":[{"mainsnak":{"snaktype":"value","property":"P100","datavalue":{"value":{"time":"+2017-01-01T00:00:00Z","timezone":0,"before":0,"after":0,"precision":9,"calendarmodel":"http://www.wikidata.org/entity/Q1985727"},"type":"time"},"datatype":"time"},"type":"statement","id":"Q9894$2D7D7966-BFDD-463E-8974-4BC1E13C3D66","rank":"normal"}],"P102":[{"mainsnak":{"snaktype":"value","property":"P102","datavalue":{"value":"Pediatr. Blood Cancer","type":"string"},"datatype":"string"},"type":"statement","id":"Q9894$431B5DBE-7B7C-49D5-9677-B6C8ED69850E","rank":"normal"}],"P103":[{"mainsnak":{"snaktype":"value","property":"P103","datavalue":{"value":"64","type":"string"},"datatype":"string"},"type":"statement","id":"Q9894$33CDA3CF-0736-45C9-9083-8B47B19218A7","rank":"normal"}],"P93":[{"mainsnak":{"snaktype":"value","property":"P93","datavalue":{"value":{"text":"A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).","language":"en"},"type":"monolingualtext"},"datatype":"monolingualtext"},"type":"statement","id":"Q9894$DF8176C3-662A-4609-83E7-0A678A767866","rank":"normal"}]},"sitelinks":{"sliswiki":{"site":"sliswiki","title":"Cooper TM, et al. Pediatr. Blood Cancer (2017) cited as Ref 631 in DOI: 10.1038/s41392-020-0110-5","badges":[],"url":"https://wikibase.slis.ua.edu/wiki/Cooper_TM,_et_al._Pediatr._Blood_Cancer_(2017)_cited_as_Ref_631_in_DOI:_10.1038/s41392-020-0110-5"}}}}}